ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept

#ALXO ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ALXO/alx-oncology-r...

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – - Third dose cohort initiated in Phase 1 trial of ALX 2004; study

#ALXO ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

www.stocktitan.net/news/ALXO/alx-oncology-a...

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update ALX Oncology (Nasdaq: ALXO) reported Q3 2025 results and a corporate update on Nov 7, 2025. Key clinical highlights from an ASPEN-06 exploratory analysis showed strong benefit for evorpacept in retained HER2-positive, CD47-high gastric cancer: ORR 65.0% vs 26.1%, median DOR 25.5 vs 8.4 months, PFS 18.4 vs 7.0 months (HR 0.39), and OS 17.0 vs 9.9 months (HR 0.63).ALX remains on track to start Phase 2 ASPEN-09-Breast Cancer enrollment in Q4 2025 with interim data expected Q3 2026. Phase 1 ALX2004 is enrolling (dose cohort 2 at 2 mg/kg) with initial safety data expected in 1H 2026. Q3 cash, cash equivalents and investments were $66.5 million, funding operations into Q1 2027. The company appointed Barbara Klencke, M.D., as interim CMO and will host a webcast on Nov 7, 2025.

#ALXO ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ALXO/alx-oncology-r...

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference ALX Oncology (NASDAQ: ALXO) presented preclinical data and the Phase 1 trial design for ALX2004, an EGFR-targeted antibody-drug conjugate, at the 2025 AACR-NCI-EORTC conference on October 23, 2025.The company reported a robust preclinical package supporting differentiation in the EGFR-ADC class, described ALX2004’s matuzumab-derived EGFR antibody, proprietary Top1i payload and linker designed to improve on-target delivery and bystander effect, and confirmed the ongoing first-in-human study (NCT07085091) for advanced/metastatic EGFR-expressing solid tumors.Enrollment began in August 2025 and initial safety data is anticipated in H1 2026.

#ALXO ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

www.stocktitan.net/news/ALXO/alx-oncology-a...

Trade Alerts, Monday September 8, 2025 – Crystal Equity Research

Small-cap stocks with bearish MACD Xs, Mon Sept 8th - #VIRC #OKUR #NBN #MOGO #JBSS #HIVE #GASS #FGEN #EQ #SNT #DYN #CCNE #ALXO #YEXT #WTI #SD #PDS #PACK #PDSB #NXDR #INVX #HE #GRNT #EGY #CYD #BFS #ALEX - More: crystalequityresearch.com/trade-alerts... - #smallcap

First-in-Class EGFR Cancer Drug: ALX Oncology Launches Groundbreaking Phase 1 Trial for Solid Tumors ALX Oncology begins Phase 1 trial of ALX2004, a first-in-class EGFR-targeted ADC for solid tumors. Initial safety data expected H1 2026. Study targets NSCLC, HNSCC, ESCC, and CRC patients.

#ALXO ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

www.stocktitan.net/news/ALXO/alx-oncology-d...

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event ALX Oncology (NASDAQ: ALXO) has announced details about ALX2004, their novel antibody-drug conjugate (ADC) designed to treat EGFR-expressing solid tumors. The drug has received FDA IND clearance and will begin clinical trials in mid-2025, with initial safety data expected in 1H 2026. ALX2004 features a unique design with an affinity-tuned EGFR antibody and proprietary linker-Top1i payload, engineered to maximize therapeutic effectiveness while reducing toxicity. Preclinical data shows superior stability compared to other ADCs, demonstrating dose-dependent activity across various tumors without significant EGFR-related skin toxicity. The Phase 1 trial will focus on patients with relapsed/refractory cancers, including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma.

#ALXO ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

www.stocktitan.net/news/ALXO/alx-oncology-h...

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update ALX Oncology (ALXO) reported Q1 2025 financial results and corporate updates. The company received FDA IND clearance for ALX2004, their novel EGFR-targeted antibody-drug conjugate, with clinical trials starting mid-2025. They're focusing on evorpacept development in combination with anti-cancer antibodies, with Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies starting mid-2025. The company won't pursue U.S. registration for gastric cancer after FDA feedback indicated accelerated approval isn't feasible. Financial highlights include cash position of $107.0 million, extending runway into Q4 2026. Q1 2025 showed reduced R&D expenses at $23.9M (down from $31.7M) and increased G&A expenses at $7.9M (up from $6.0M). Net loss improved to ($30.8M) compared to ($35.6M) in Q1 2024.

#ALXO ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ALXO/alx-oncology-r...

Breakthrough Cancer Drug Gets FDA Green Light: ALX2004 Targets Multiple Solid Tumors Novel antibody-drug conjugate shows promise for treating various cancers including breast, lung, and colorectal. First human trials set for 2025. Full analysis inside.

#ALXO ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

www.stocktitan.net/news/ALXO/alx-oncology-r...

Can ALX Oncology's 49% Cancer Trial Success Transform Gastric Cancer Treatment? Promising Phase 2 results for evorpacept with 48.9% response rate in gastric cancer. Strategic restructuring extends $131.3M cash runway through 2026.

#ALXO ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ALXO/alx-oncology-r...

Can ALX Oncology's Pipeline Progress Outweigh Its 30% Staff Cuts? Key R&D Day Revelations ALX Oncology reveals new breast and colorectal cancer trials for evorpacept, plans Q1 2025 IND for ALX2004 ADC, while reducing workforce by 30% to extend cash runway to Q4 2026.

#ALXO ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

www.stocktitan.net/news/ALXO/alx-oncology-h...

JUST IN: ( NASDAQ: #ALXO ) Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines

#StockMarket #News

JUST IN: ( NASDAQ: #ALXO ) ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

#StockMarket #News

#ALXO rippin

#ALXO ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/ALXO/alx-oncology-t...

#ALXO ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

www.stocktitan.net/news/ALXO/alx-oncology-a...

Just In: ( NASDAQ: #ALXO ) ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

#StockMarket #News